MEDI-551

DRUG4 trials

Sponsors

MedImmune LLC, AstraZeneca

Conditions

Advanced B Cell MalignanciesB-cell MalignanciesBlood CancerCancerChronic Lymphocytic Leukemia (CLL)Scleroderma

Phase 1

A Study of the Safety and Tolerability of MEDI-551 in Scleroderma

CompletedNCT00946699

MedImmune LLCScleroderma

Start: 2010-03-31End: 2014-03-31Updated: 2014-11-13

A Clinical Study Using MEDI-551 in Adult Participants With Relapsed or Refractory Advanced B-Cell Malignancies

CompletedNCT00983619

MedImmune LLCB-cell Malignancies, Cancer

Start: 2010-04-16End: 2019-03-21Updated: 2020-05-13

A Phase 1, Dose-escalation Study of MEDI-551 in Japanese Adult Patients With Relapsed or Refractory Advanced B-cell Malignancies

CompletedNCT01957579

AstraZenecaAdvanced B Cell Malignancies, Blood Cancer

Start: 2011-05-25End: 2015-09-15Updated: 2017-06-12

Phase 2

A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

CompletedNCT01466153

MedImmune LLCChronic Lymphocytic Leukemia (CLL)

Start: 2012-02-07End: 2016-01-08Updated: 2017-05-31

Related Papers

Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study

Arthritis Research & Therapy2016-06-0778 citations

Results of a Phase 2 Study of MEDI-551 and Bendamustine Vs Rituximab and Bendamustine in Relapsed or Refractory Chronic Lymphocytic Leukemia

Blood2014-12-063 citations

Phase 2 open-label study of MEDI-551 and bendamustine versus rituximab and bendamustine in adults with relapsed or refractory CLL.

Journal of Clinical Oncology2014-05-205 citations